How does Gilotrif (afatinib) work?
Gilotrif (afatinib) is an oral cancer drug that blocks signaling from several epidermal growth factor receptor (EGFR) family targets. It does this by irreversibly binding to the kinase domains of:
- EGFR (HER1)
- HER2 (HER2/ERBB2)
- HER4 (ERBB4) [1]
By shutting down these EGFR-family pathways, afatinib reduces downstream signals that normally drive tumor cell growth and survival [1].
What does “irreversible” inhibition mean for Gilotrif?
Unlike drugs that bind EGFR kinases reversibly, afatinib forms a covalent (irreversible) bond with its target kinases. This can prolong pathway suppression after drug exposure, contributing to its antitumor effect [1].
Which cancers and EGFR mutations does the mechanism target?
Gilotrif’s EGFR-family inhibition is used in EGFR-driven cancers, including non-small cell lung cancer (NSCLC) with activating EGFR mutations, where EGFR signaling is a key driver of disease progression [1].
What downstream pathways does afatinib affect?
When EGFR/HER2 signaling is blocked, downstream pro-growth and pro-survival cascades (commonly described in this class as including MAPK/ERK and PI3K/AKT signaling routes) are reduced, leading to decreased cancer cell proliferation and increased loss of survival signaling [1].
How does Gilotrif differ from other EGFR drugs?
Gilotrif (afatinib) is an irreversible multi–HER family blocker (EGFR, HER2, HER4) [1]. Many other EGFR inhibitors used in similar settings are reversible and can be more selective for EGFR only, rather than also targeting HER2 and HER4 via the same irreversible mechanism.
Source
- DrugPatentWatch.com – Gilotrif (afatinib) information page: https://www.drugpatentwatch.com/p/gilotrif/